Literature DB >> 8639849

Integrin function in chronic lymphocytic leukemia.

A M Vincent1, J C Cawley, J Burthem.   

Abstract

Integrins are central to many aspects of the tissue localization of normal and malignant lymphocytes. We examined how integrin function, rather than simple expression, might determine disease behavior in chronic lymphocyte leukemia (CLL). Using fluorescence-activated cell sorting (FACS) and immunoprecipitation, we first established the precise integrin heterodimer expression of a representative group of CLL patients (beta1 consistently present, with variable alpha 3, alpha 4, and alpha 5; alpha 4 beta 7 often expressed; alpha L beta 2 high; alpha V beta 3 absent). Regarding function, we initially examined the ability of CLL cells to interact with endothelium, because such interaction is the initial event determining the entry of CLL lymphocytes into tissues. The abnormal lymphocytes were shown to bind at low levels to unstimulated endothelium via beta 2/intercellular adhesion molecule (ICAM). However, when the endothelium was stimulated, markedly enhanced interaction with endothelium was observed in approximately half the cases; in these patients, the neoplastic population expressed alpha 4 beta 1, which conferred the ability to adhere strongly to stimulated endothelium via the alpha 4 beta 1 ligand, vascular cellular adhesion molecule-1 (VCAM-1). In relation to the migration of CLL cells within tissues, the abnormal lymphocytes showed differential binding to various adhesive proteins; they did not attach to basement membrane components, but displayed variable adhesion to fibronectin (FN). Finally, we examined the role of cell activation in these processes, and showed that activated CLL lymphocyte populations showed an increased capacity to adhere to both endothelium and matrix. Moreover, ex vivo CLL cells showed no capacity to migrate through endothelium/stroma, but were able to do so after cytokine stimulation. These studies show how the constitutive integrin expression/function, the intrinsic activation state of the cell, and the capacity of cytokines to modify integrin-mediated function all combine to determine the different patterns of clinical disease observed in CLL.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8639849

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Halogenated benzimidazole carboxamides target integrin alpha4beta1 on T-cell and B-cell lymphomas.

Authors:  Richard D Carpenter; Arutselvan Natarajan; Edmond Y Lau; Mirela Andrei; Danielle M Solano; Felice C Lightstone; Sally J Denardo; Kit S Lam; Mark J Kurth
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.

Authors:  Wan Zhang; Peng Huang
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

3.  CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells.

Authors:  F M Rossi; A Zucchetto; E Tissino; M Dal Bo; R Bomben; C Caldana; F Pozzo; G Del Poeta; D Rossi; G Gaidano; V Gattei
Journal:  Leukemia       Date:  2013-11-08       Impact factor: 11.528

4.  Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment.

Authors:  Ye Chen; Rodrigo Jacamo; Yue-xi Shi; Rui-yu Wang; Venkata Lokesh Battula; Sergej Konoplev; Dirk Strunk; Nicole A Hofmann; Andreas Reinisch; Marina Konopleva; Michael Andreeff
Journal:  Blood       Date:  2012-04-05       Impact factor: 22.113

5.  Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin.

Authors:  Richard D Carpenter; Mirela Andrei; Olulanu H Aina; Edmond Y Lau; Felice C Lightstone; Ruiwu Liu; Kit S Lam; Mark J Kurth
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

6.  Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

Authors:  Zhihong Zeng; Yue Xi Shi; Ismael J Samudio; Rui-Yu Wang; Xiaoyang Ling; Olga Frolova; Mark Levis; Joshua B Rubin; Robert R Negrin; Elihu H Estey; Sergej Konoplev; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

7.  α7 helix region of αI domain is crucial for integrin binding to endoplasmic reticulum chaperone gp96: a potential therapeutic target for cancer metastasis.

Authors:  Feng Hong; Bei Liu; Gabriela Chiosis; Daniel T Gewirth; Zihai Li
Journal:  J Biol Chem       Date:  2013-05-13       Impact factor: 5.157

8.  CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.

Authors:  Tait D Shanafelt; Susan M Geyer; Nancy D Bone; Renee C Tschumper; Tom E Witzig; Greg S Nowakowski; Clive S Zent; Tim G Call; Betsy Laplant; Gordon W Dewald; Diane F Jelinek; Neil E Kay
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

Review 9.  Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs.

Authors:  Uta E Höpken; Armin Rehm
Journal:  J Mol Med (Berl)       Date:  2012-05-11       Impact factor: 4.599

Review 10.  Tumor-targeting peptides from combinatorial libraries.

Authors:  Ruiwu Liu; Xiaocen Li; Wenwu Xiao; Kit S Lam
Journal:  Adv Drug Deliv Rev       Date:  2016-05-19       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.